Apparently they actually do have a pipeline that is in advanced trials and actually works.... And Siga had years ahead of them as a publicly funded company too. Once again, it all comes down to management, doesn't it?
Oh for God's sake! That is a scurrilous post. Their positive results were this: "CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation." That has nothing to do with smallpox, and nothing to do with CMXR's chances of sharing in further stockpiling of anti-smallpox, and NOTHING TO DO WITH SIGA. SIGA is still years ahead of CMRX in anti-SMALLPOX results. Golong must have goneshort.
OK Kage.....Since I know that English is a second language for you, let's try this....
We all know that Siga has an unapproved (by the FDA) smallpox anti virus that BARDA purchased years ago and is currently being produced by the company pursuant to that contract.
My reference to CMRX was in respect to the OTHER products that they have in development which is part of their "pipeline" in addition to their smallpox antiviral. Being years ahead in "anti-SMALLPOX results" (I have no idea what that refers to since it is not a clinical term, but apparently Kege language) means zipo. Please post when the FDA approves ST-246....no let's try approves a SPA for starting clinical trials....and you may have something to talk about.
When you learn that the term "pipeline" refers to other products in development other that a company's lead product, then you'll hopefully understand that CMRX apparently has one, and just reported positive Phase II results on it. When Siga has something to report other than insiders exercising stock options, please wake us up.